Bullish case
$34 to $38
More likely if adjusted EPS compounds near high-single digits, Novum IQ remediation risk fades, cost programs lift margins, and investors reward Baxter with a mid-teens earnings multiple.
Baxter International Inc. research snapshot
BAX AI Stock Analysis
BAX AI stock analysis currently reads Baxter International as a medical products turnaround rather than a clean compounder. The company has durable hospital relationships, essential IV, infusion, nutrition, surgical, and injectable products, and improving cash generation after the Kidney Care sale. The forecast is scenario-based instead of a precise price prediction because GAAP losses, restructuring costs, Novum IQ pump issues, and debt reduction needs still limit investment certainty.
Current price
$22.86
Market cap
$11.81 billion
AI score
54 / 100
Rating
Turnaround medical products operator, high execution risk
Trend status
Short-term technical rebound above key moving averages, but fundamentals remain in repair mode
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Baxter is a long-listed NYSE company with SEC filings, investor materials, analyst coverage, market data, and technical indicator coverage.
- bias Check
- The main AI research risk is overfitting to a turnaround narrative after the stock fell sharply in prior years. This page tests the opposite case: low growth, margin pressure, product remediation costs, and balance sheet drag may offset the apparent valuation discount.
- ai Confidence
- High for reported 2025 revenue, share count, Q1 2026 cash, debt, and recent market data. Medium for earnings power because GAAP results include restructuring, amortization, separation costs, and other special items.
- investment Certainty
- Medium-low. Baxter sells necessary healthcare products, but a good product portfolio does not automatically equal a high-certainty equity case while profitability and execution are still being reset.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Baxter sells essential hospital products with recurring demand, but current quality is diluted by weak margins, recalls, and transformation costs. | Medium |
| Moat | Hospital relationships, regulatory know-how, manufacturing scale, and product breadth create switching friction, while generic injectables and devices face pricing pressure. | Medium |
| Management | CEO Andrew Hider is early in the role and is pursuing simplification, cost reduction, and post-Kidney Care execution improvement. | Medium-low |
| Financial trend | FY2025 sales were about $11.24 billion, but Baxter reported a $957 million net loss attributable to stockholders. Q1 2026 cash flow improved. | High for reported data |
| Valuation | At $22.86, BAX trades near 11.7x the midpoint of 2026 adjusted EPS guidance and 16.3x trailing free cash flow, but GAAP PE is not meaningful. | Medium |
| Technical trend | The stock is above 50-day and 200-day moving averages, but RSI near 70-plus shows the rebound is extended in the short term. | Medium |
| Risk level | Key risks are product remediation, low organic growth, tariff and manufacturing pressure, leverage, healthcare purchasing pressure, and execution risk. | Medium-high |
| AI confidence | Data confidence is high because sources are rich. Return confidence is lower because the investment case depends on operational repair. | High data confidence |
| Investment certainty | BAX may be attractive for turnaround investors, but the business does not yet show the clean margin profile or growth certainty of a high-quality healthcare compounder. | Medium-low |
BAX AI stock forecast
BAX AI Stock Forecast Scenarios
The BAX AI stock forecast should be read as a range of operating scenarios, not a guaranteed price target. Using a July 8, 2026 price reference near $22.86 and the 2026 adjusted EPS guidance midpoint of $1.95, the three-year model produces about $13 in a bear case, $26 in a base case, and $37 in a bullish case before dividends.
Base case
$24 to $27
More likely if sales grow slowly, 2026 adjusted EPS near $1.95 becomes a stable earnings base, cash generation funds debt reduction, and the stock holds a low-teens earnings multiple.
Bearish case
$12 to $15
More likely if recalls, tariffs, manufacturing absorption, weak injectables demand, or restructuring costs keep GAAP losses and free cash flow volatility in focus.
BAX AI technical analysis
BAX AI Technical Analysis
BAX AI technical analysis is constructive but extended as of the July 8, 2026 data cutoff. StockAnalysis reported a July 7 close of $22.86, while AltIndex showed the 50-day moving average above the 200-day moving average and RSI above 70.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $22.86 | StockAnalysis reported the July 7, 2026 close at $22.86. |
| Near support | $20.46 to $20.61 | ChartMill listed this as a support zone from moving averages in the daily time frame. |
| Lower support zone | $18.96 to $19.30 | This zone overlaps the 200-day moving average area and would matter if the rebound fails. |
| Resistance | $22.25 to $22.51 | AltIndex and ChartMill both place recent resistance around the low $22 area, which BAX was testing at the data cutoff. |
| Higher resistance | $24.45 | ChartMill listed $24.45 as a daily horizontal resistance level. |
| Moving averages | 50-day $20.30, 200-day $19.10 | AltIndex reported a bullish 50-day above 200-day setup. |
| Momentum | RSI 69.96 to 72.1 | StockAnalysis and AltIndex both showed momentum near or above the overbought threshold. |
| Volume | 20-day average 6.86M shares | StockAnalysis reported average 20-day volume of 6,855,589 shares. |
| Invalidation | Close below $19 | A close below the lower support zone and 200-day area would weaken the rebound framework. |
BAX AI trading strategy
BAX AI Trading Strategy Framework
The BAX AI trading strategy below is a rules-based research framework, not personal advice. It combines turnaround milestones, technical confirmation, and predefined invalidation levels.
Trend-following setup
Watch for BAX to hold above the $20 to $21 support area and build a base above the 50-day and 200-day moving averages after the RSI cools from overbought levels.
Use a close below $19 or a renewed earnings guidance cut as a rules-based invalidation signal.
Mean-reversion setup
If BAX pulls back toward $20 without a new operational downgrade, compare price stabilization with free cash flow, pump remediation updates, and Q2 earnings guidance.
Avoid treating a low adjusted PE as enough support if GAAP losses, debt, or product holds worsen.
Fundamental monitor
Track Medical Products & Therapies sales, Healthcare Systems & Technologies margin, Pharmaceuticals supply constraints, Novum IQ status, free cash flow, net debt, and restructuring charges.
Position sizing should assume that a healthcare turnaround can miss targets for several quarters before the equity narrative resets.
Investment research summary
Four-master Research Compression
Business essence
Baxter sells essential healthcare products used inside hospitals and care settings. Customers pay for reliability, regulatory compliance, clinical workflow continuity, and dependable supply rather than for a pure technology edge.
Moat
The moat comes from installed relationships, regulated manufacturing, supply chain scale, product breadth, and the cost of disrupting hospital workflows. It is not absolute because buyers can pressure price and some categories have generic or device competition.
Munger risk inversion
The thesis fails if the company cannot convert cost cuts into margins, if Novum IQ remediation drags on, if tariffs or manufacturing absorption pressure persist, or if leverage limits strategic flexibility.
Management
Andrew Hider became CEO in 2025 and is judged mainly on execution: simplifying the portfolio after Kidney Care, improving quality systems, restoring margins, and using cash flow for balance sheet repair.
Industry trend
Healthcare demand is durable, but Baxter is not in the fastest-growth segment of medtech. The long-term trend is stable hospital utilization, while the near-term issue is operational performance.
Valuation and margin of safety
The stock screens inexpensive on adjusted EPS guidance, but GAAP losses and balance sheet leverage reduce the margin of safety. A better entry needs either proof of earnings repair or a larger price discount.
Source-backed data
BAX Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BAX closing price | $22.86 on July 7, 2026 | StockAnalysis statistics | July 8, 2026 |
| Shares outstanding | 516.47 million | StockAnalysis statistics | July 8, 2026 |
| Market cap | $11.81 billion calculated from $22.86 x 516.47M shares | Pineify financial_rigor.py calculation | July 8, 2026 |
| FY2025 net sales | $11.24 billion from continuing operations | Baxter 2025 Form 10-K | July 8, 2026 |
| FY2025 net loss attributable to Baxter stockholders | $957 million loss | Baxter 2025 Form 10-K | July 8, 2026 |
| Q1 2026 net sales | $2.70 billion, up 3% year over year | Baxter Q1 2026 results | July 8, 2026 |
| Q1 2026 free cash flow | $76 million | Baxter Q1 2026 earnings call transcript | July 8, 2026 |
| Q1 2026 cash and debt | $2.02 billion cash and $8.62 billion long-term debt | Baxter Q1 2026 10-Q summary | July 8, 2026 |
| Valuation ratios | Forward PE 11.67, PS 1.04, PB 1.95, P/FCF 16.33 | StockAnalysis statistics | July 8, 2026 |
| Technical indicators | 50-day MA $20.30, 200-day MA $19.10, RSI 72.1 | AltIndex technical analysis | July 8, 2026 |
Frequently Asked Questions
Read the ABT AI stock analysisCompare BAX with BKR AI stock analysisExplore Pineify AI Stock PickerGenerate a stock trading strategy
This BAX AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and may be wrong if Baxter results, product issues, valuation multiples, interest rates, or market conditions change.